SFAM
AKRO

Springhill Fund Asset Management’s Akero Therapeutics AKRO Stock Holding History

Springhill Fund Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,925
Closed -$807K – 1
2025
Q1 		$807K Sell
19,925
-131,275
-87% -$5.56M 3.87% 9
2024
Q4 		$4.21M Buy
+151,200
New +$4.58M 6.83% 8

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Springhill Fund Asset Management's AKRO Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 19,925 shares — an estimated $807K sold.

Springhill Fund Asset Management first reported a position in AKRO in Q4 2024 and held it in 2 quarters. The position peaked at $4.21M in Q4 2024. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Springhill Fund Asset Management reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 19,925 Akero Therapeutics shares in Q2 2025, an estimated $807K.
  • Springhill Fund Asset Management first reported a position in Akero Therapeutics in Q4 2024 and held it in 2 quarters.
  • Springhill Fund Asset Management's Akero Therapeutics position peaked at $4.21M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.